fda approves first oral glp-1 obesity drug august 21 2025 The approved a new pill from Eli Lilly on Wednesday. The drug, called Foundayo, is the second GLP-1 weight-loss pill. CBS News' Dr. LaPook has more on the new medication Scam weight-loss drops marketed to

In the SURPASS 2 trial, Tirzepatide at all doses (5mg, 10mg and 15mg) was found to result in greater weight loss than semaglutide 1mg

Effects of Semaglutide Treatment on Psoriatic Lesions in Obese Patients with Type 2 Diabetes Mellitus: An Open-Label, Randomized Clinical Trial

No patients receiving GLP-1 RAs were excluded due to loss of follow-up, while 8 patients (0.2%) who did not receive GLP-1 RAs were excluded for this reason (Supplemental Table 3)

As estrogen levels embark on their downward rollercoaster throughout perimenopause, muscle mass maintenance becomes more and more challenging

Pre-existing cardiovascular disease and heart failure were more prevalent among participants in the insulin group (34.6% and 14.8%) than in the other groups (25.6% and 8.7% with GLP-1RA, 23.8% and 7.6% with SGLT2i and 18.9% and 4.9% in the miscellany group, respectively) (Table 1)

[DOI] [PubMed] [Google Scholar] 711.Kohno D., Sone H., Tanaka S., Kurita H., Gantulga D., Yada T